Allogene Therapeutics, Inc. (ALLO)
$3.51
+0.01
(+0.29%)▲
Insights on Allogene Therapeutics, Inc.
Decreasing Revenue
Revenue is down for the last 4 quarters, 52.0K → 21.0K (in $), with an average decrease of 22.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -61.31M → -85.77M (in $), with an average decrease of 39.9% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 73.6%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 334.3%
Performance
- $3.46$3.58$3.51
1.42%
Downside
Day's Volatility :3.35%
Upside
1.96%
- $2.23$6.89$3.51
36.47%
Downside
52 Weeks Volatility :67.63%
Upside
49.06%
Returns
| Period | Allogene Therapeutics, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 9.69% | -0.7% | 0.0% |
6 Months | 13.96% | 6.6% | 0.0% |
1 Year | -26.88% | 3.7% | -1.5% |
3 Years | -89.15% | 14.0% | -21.8% |
Highlights
Market Capitalization | 591.8M |
Book Value | $3.04 |
Earnings Per Share (EPS) | -2.09 |
Wall Street Target Price | 9.69 |
Profit Margin | 0.0% |
Operating Margin TTM | 163475.0% |
Return On Assets TTM | -26.84% |
Return On Equity TTM | -55.51% |
Revenue TTM | 95.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | -55.300000000000004% |
Gross Profit TTM | 243.0K |
EBITDA | -300.3M |
Diluted Eps TTM | -2.09 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.65 |
EPS Estimate Next Year | -1.57 |
EPS Estimate Current Quarter | -0.45 |
EPS Estimate Next Quarter | -0.44 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 176.07%
Technicals Summary
Sell
Neutral
Buy
Allogene Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Allogene Therapeutics, Inc. | -16.33% | 13.96% | -26.88% | -89.15% | -86.47% |
 Moderna, Inc. | -0.79% | 20.27% | -27.48% | -36.11% | 359.53% |
 Regeneron Pharmaceuticals, Inc. | -6.12% | 9.1% | 11.53% | 80.35% | 170.35% |
 Novo Nordisk A/s | -6.29% | 23.82% | 46.7% | 242.59% | 414.69% |
 Vertex Pharmaceuticals Incorporated | -4.44% | 6.95% | 20.9% | 79.35% | 133.77% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Allogene Therapeutics, Inc. | NA | NA | NA | -1.65 | -0.56 | -0.27 | NA | 3.04 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.71 | 25.71 | 1.46 | 45.13 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 46.58 | 46.58 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.42 | 28.42 | 0.53 | 16.73 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Allogene Therapeutics, Inc. | Buy | $591.8M | -86.47% | NA | 0.0% |
Moderna, Inc. | Buy | $39.8B | 359.53% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.1B | 170.35% | 25.71 | 30.14% |
Novo Nordisk A/s | Buy | $551.2B | 414.69% | 46.58 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $101.9B | 133.77% | 28.42 | 36.68% |
Institutional Holdings
FMR Inc
14.93%TPG GP A, LLC
11.07%BlackRock Inc
5.92%Vanguard Group Inc
5.34%JPMorgan Chase & Co
4.08%Goldman Sachs Group Inc
3.95%
Corporate Announcements
Allogene Therapeutics, Inc. Earnings
Allogene Therapeutics, Inc.’s price-to-earnings ratio stands at None
Read More
Company Information
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
Organization | Allogene Therapeutics, Inc. |
Employees | 232 |
CEO | Dr. Arie S. Belldegrun F.A.C.S., M.D. |
Industry | Health Technology |
